HOME >> BIOLOGY >> NEWS
Liver transplant patients gain same benefits from CellCept as kidney transplant patients

25th May 2005, Basel, Switzerland New data reported in over 90 abstracts presented at the American Transplant Congress in Seattle show that liver transplant patients taking the immunosuppressant CellCept are gaining the same positive benefits already demonstrated in kidney transplant patients. This is good news for patients as the demand for liver transplants is increasing, with many of the cases directly resulting from chronic hepatitis C virus (HCV) infection.

Benefits seen with CellCept include:

  • Reduced risk of acute rejection, especially in patients infected with HCV
    • graft rejection is of particularly high risk in HCV patients and is associated with increased morbidity and decreased patient and graft survival (Abstract 928)

  • Safe and effective steroid-free regimens for HCV patients
    • steroids are known to have a negative impact on the progression of HCV, which can result in liver fibrosis (Abstract 475)

  • Optimal kidney function
    • CellCept taken with a low dose of tacrolimus showed a trend towards improved kidney function (Abstract 1240). CellCept is proven to promote excellent kidney function early after kidney transplantation in renal patients taking tacrolimus(1)

  • Less liver fibrosis
    • recipients taking CellCept-based regimens showed a significant reduction in the inflammation and structural changes that can lead to liver failure (Abstract 1446)

  • No increased risk of malignancy
    • the addition of CellCept to maintenance immunosuppression that includes tacrolimus and corticosteroids did not increase the risk of death due to malignant complications (Abstract 930). This confirms previous data as seen in kidney transplant recipients(2)

"It's really exciting to see liver transplant recipients benefiting from CellCept in the same way as kidney transplant patients.
'"/>

Contact: Vicky Singlehurst
vicky.singlehurst@ketchum.com
+44-207-611-3523
Ketchum
25-May-2005


Page: 1 2

Related biology news :

1. Liverpool amongst first in UK to install unique DNA sequencing technology
2. University of Liverpool launches 10 million small animal teaching hospital
3. Liverpool scientists work to improve water quality in Ghana
4. Liver regeneration may be simpler than previously thought
5. 2.5M boost for marine biology in Liverpool
6. Liver signal critical for insulins brain action
7. International scientists to present MRSA research in Liverpool
8. UC Davis, Lawrence Livermore researchers
9. Liver cancer linked to cellular repair pathway
10. Liver metabolism goes to pot
11. Liverpool vet creates pain relief diet for arthritic dogs

Post Your Comments:
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/10/2014)... on U.S. store shelves in early 2010, and people ... small packets can be tossed into a washing machine ... powder. The convenience, though, has come with risks for ... Nationwide Children,s Hospital found that from 2012 through 2013, ... younger than 6 years of age swallowing, inhaling, or ...
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3
(Date:11/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a ... pharmaceutical company, today announced it has submitted an additional ... and Drug Administration (FDA), which brings the Company,s total ... eighteen submissions now pending at the FDA. ... the Company, commented, "Our team here at IGI has ...
(Date:11/24/2014)... WASHINGTON , Nov. 24, 2014  Last ... G.K. Butterfield (D-NC) took a bold ... diseases by introducing the OPEN Act. Original co-sponsors ... Hastings (D-FL). The Act will incentivize drug makers ... life-threatening rare diseases and pediatric cancers, which opens ...
(Date:11/24/2014)...   First published ... Elsevier , a world-leading provider of scientific, technical ... the launch of the latest title in the Current ... Food Science . Current ... new platform to keep up-to-date with the expanding volume of ...
(Date:11/24/2014)... Washington, USA (PRWEB) November 23, 2014 One ... dynamic field of optics and photonics is now available to ... or very low cost. SPIE, the international society for ... access to the complete SPIE Digital Library available ... subsidized price. , “Light-based technologies are integral to all areas ...
Breaking Biology Technology:IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2
Cached News: